## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

| TAKEDA PHARMACEUTICALS U.S.A., INC. |                         |
|-------------------------------------|-------------------------|
| Plaintiff,                          | <br>                    |
| v. )                                | C.A. No. 19-cv-2216-RGA |
| MYLAN PHARMACEUTICALS INC.,         | <br>                    |
| Defendant. )                        |                         |

## MYLAN PHARMACEUTICALS INC.'S RESPONSE TO PAR PHARMACEUTICAL INC.'S MOTION TO INTERVENE

On December 2, 2019, Plaintiff Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") filed its Complaint in this action against Defendant Mylan Pharmaceuticals Inc. ("MPI"). D.I. 2. Three days later, on December 5, 2019, Takeda filed a Motion for a Preliminary Injunction. D.I. 12. On December 20, 2019, non-party Par Pharmaceuticals Inc. ("Par") filed a Motion to Intervene. D.I. 26. MPI takes no position on Par's Motion to Intervene to the extent Par seeks to intervene in this action. MPI, however, does object to any undue delay in the briefing and resolution of Takeda's Motion for a Preliminary Injunction, which is proceeding pursuant to an expedited schedule agreed to by the parties and so-ordered by the Court. D.I. 7, 44. Accordingly, if the Court determines both to grant Par's Motion to Intervene and to permit Par to participate in briefing on Takeda's Motion for a Preliminary Injunction, MPI respectfully requests that any participation by Par be pursuant to the terms of the stipulation agreed to between MPI and Par and submitted to the Court on January 6, 2020. D.I. 55. Finally, MPI's position on Par's Motion to Intervene is without waiver of any and all defenses MPI may assert with respect to the

allegations and claims in Par's proposed Complaint-in-Intervention, including via motion to dismiss, and in no way constitutes an admission with respect to those allegations and claims.

Dated: January 7, 2020 Respectfully Submitted by:

## OF COUNSEL:

Stu Williams
Michael S. Sommer
Jessica L. Margolis
Sheryl Shapiro Bassin
WILSON SONSINI GOODRICH &
ROSATI, P.C.
1301 Avenue of the Americas, 40th Floor
New York, NY 10019
Telephone: (212) 999-5800
swilliams@wsgr.com
msommer@wsgr.com
jmargolis@wsgr.com
sbassin@wsgr.com

Nicole Stafford
Shyam Palaiyanur
WILSON SONSINI GOODRICH &
ROSATI, P.C.
900 S. Capital of Texas Hwy.
Las Cimas IV, Fifth Floor
Austin, TX 78746
Telephone: (512) 338-5400
nstafford@wsgr.com
spalaiyanur@wsgr.com

David S. Steuer WILSON SONSINI GOODRICH & ROSATI, P.C. 650 Page Mill Road Palo Alto, CA 94304 Telephone: (650) 493-9300 dsteuer@wsgr.com

## /s/ Kenneth L. Dorsney

Kenneth L. Dorsney (No. 3726) MORRIS JAMES LLP 500 Delaware Avenue, Suite 1500 Wilmington, DE 19801-1494 (302) 888-6800 kdorsney@morrisjames.com

Attorneys for Defendant Mylan Pharmaceuticals Inc.